| Literature DB >> 26124878 |
Fatemeh Sheikhi Mehrabadi1, Hanxiang Zeng2, Mark Johnson2, Cathleen Schlesener1, Zhibin Guan2, Rainer Haag1.
Abstract
The success of siREntities:
Keywords: arginine; dendritic polyglycerolamine; histidine; multivalent vector; siRNA delivery
Year: 2015 PMID: 26124878 PMCID: PMC4464416 DOI: 10.3762/bjoc.11.86
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Scheme 1Synthesis of multivalent arginine and histidine functionalized dPG-NH2 50%. The depicted dPG-NH2 represents only a small idealized fragment of a 10 kDa molecule.
Summary of AAdPG vectors and their corresponding polyplex characterization.
| Compound | Zeta potential (mV)a | diameter | PDIc | (Arg) %d | (His) %d | Arg:His |
| dPG-NH2 50% | 10.0 ± 0.2 | 124.1 ± 0.7 | 0.07 | – | – | – |
| dPG-13Arg13His | 10.9 ± 0.8 | 97.17 ± 0.87 | 0.13 | 13 | 13 | 1:1 |
| dPG-13Arg | 10.6 ± 0.9 | 60.04 ± 1.2 | 0.18 | 13 | – | – |
| dPG-13His | 10.3 ± 0.3 | 70.23 ± 0.8 | 0.17 | – | 13 | – |
| dPG-8Arg30His | 11.0 ± 0.9 | 104.9 ± 0.45 | 0.18 | 8 | 30 | ~1:3 |
aζ were measured at pH 7.4; bintensity distributions are reported; cPDI of polyplexes were determined by DLS; ddegree of functionalization on dPG which were determined by 1H NMR spectroscopy.
Figure 1Agarose gel electrophoresis retardation assay of AAdPGs/siRNA polyplexes. (A) dPG-13Arg13His, (B) dPG-13Arg, (C) dPG-13His, (D) dPG-8Arg30His, (E) dPG-NH2 50%, and (F) dPG-NH2 90%. Naked siRNA always appears in the first lane. The numbers on the top of each lane correspond to the different N/P ratios.
Figure 2Size measurements of dPG-NH2 50% and AAdPGs/siRNA complexes. Intensity distributions of all polyplexes are depicted.
Figure 3The result of MTT assay on a NIH 3T3 cell line transfected with AAdPG, dPG-NH2 50%, and 90%/siRNA polyplexes at different N/P ratios with 100 nM siRNA concentration.
Figure 4Cell viability versus transfection efficiency of dPG-8Arg30His and dPG-NH2 90% at N/P ratio 30.
Figure 5Summary of transfection results versus viability of AAdPGs with various Arg and His composition ratio at N/P ratio 30.
Figure 6Confocal images of NIH 3T3 cells treated with Cy3-siRNA/vector complexes: (A) naked siRNA, (B) lipofectamine, (C) dPG-13His, (D) dPG-13Arg, and (E) mean Cy-3 fluorescence intensity of 3T3 cells treated with Cy3-siRNA/vector complexes assessed by FACS.